Senti Biosciences (SNTI) said Monday that two of three acute myeloid leukemia patients treated with its Senti-202 investigational cell therapy for relapsed or refractory hematologic malignancies, or blood cancers, achieved complete remission in a phase 1 trial.
Both patients, who were treated at the lowest dose level, showed no measurable residual disease after treatment and maintained remission for over four and three months, respectively, the company said.
The therapy was well-tolerated, with no dose-limiting toxicities reported, Senti Biosciences said. Enrolment for a dose escalation phase is ongoing, with additional data expected in 2025, Senti added.
Shares of the company soared over 141% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。